@article{65b9f0d0dfa44102bedffaf0945022c7,
title = "Cardiovascular Safety of Nilotinib in Parkinson's Disease",
keywords = "nilotinib, Parkinson's disease",
author = "Sean Tan and Diva Baggio and Jake Shortt and Brian Ko",
note = "Funding Information: J.S. has received honoraria and served on advisory committee for Novartis, which manufactures nilotinib, discussed in this letter. J.S. has also received honoraria from Bristol Myer Squibb, which manufactures the tyrosine kinase inhibitor dasatinib, and Specialised Therapeutics Australia, which manufactures the tyrosine kinase inhibitor ponatinib. B.K. has received honoraria and served on the advisory committee for Novartis, which manufactures nilotinib, which is discussed in this letter. B.K. has also received honoraria from Bristol Myer Squibb, which manufactures the tyrosine kinase inhibitor dasatinib, and Specialised Therapeutics Australia, which manufactures the tyrosine kinase inhibitor ponatinib. Monash Haematology has received research funding from Bristol Myer Squibb, which manufactures the tyrosine kinase inhibitor dasatinib. The remaining authors have nothing to disclose. Relevant conflicts of interest/financial disclosures: Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",
year = "2021",
month = sep,
doi = "10.1002/mds.28733",
language = "English",
volume = "36",
pages = "2217",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley & Sons",
number = "9",
}